Bryce D. Carmine
Chairman at KAZIA THERAPEUTICS LIMITED
Net worth: 43 716 $ as of 2023-11-29
Profile
Bryce D.
Carmine is currently the Chairman at Kazia Therapeutics Ltd.
and a Non-Executive Director at HaemaLogiX Pty Ltd.
Previously, he served as the Chairman at Eli Lilly Australia Pty Ltd.
in 1995, as well as the Director at ImClone LLC.
He also held the position of Executive Vice President at Eli Lilly & Co. in 2011.
From 1995 to 1999, he was the President & General Manager at Eli Lilly Japan KK.
Additionally, he served as the General Manager at Daewoong-Lilly Pharmaceutical Co. Mr. Carmine obtained his undergraduate degree from Massey University in 1973.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
KAZIA THERAPEUTICS LTD
0.36% | 2023-03-12 | 856,681 ( 0.36% ) | 43 716 $ | 2023-11-29 |
Bryce D. Carmine active positions
| Companies | Position | Start |
|---|---|---|
| KAZIA THERAPEUTICS LIMITED | Chairman | 2024-01-17 |
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Director/Board Member | - |
Former positions of Bryce D. Carmine
| Companies | Position | End |
|---|---|---|
| ELI LILLY AND COMPANY | Director/Board Member | 2011-05-04 |
Eli Lilly Japan KK
 Eli Lilly Japan KK Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Japan KK is a Japanese company that manufactures and trades pharmaceutical products. The company is based in Kobe, Japan. | President | 1999-05-31 |
Eli Lilly Australia Pty Ltd.
 Eli Lilly Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Eli Lilly Australia Pty Ltd. manufactures and supplies pharmaceutical products. It develops medicines for diabetes, cancer, immunology, and pain. The company was founded in 1960 and is headquartered in West Ryde, Australia. | Chairman | 1994-12-31 |
| Daewoong-Lilly Pharmaceutical Co. | Corporate Officer/Principal | - |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Director/Board Member | - |
Training of Bryce D. Carmine
| Massey University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| KAZIA THERAPEUTICS LIMITED | Health Technology |
| Private companies | 5 |
|---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Eli Lilly Japan KK
Eli Lilly Japan KK Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Japan KK is a Japanese company that manufactures and trades pharmaceutical products. The company is based in Kobe, Japan. | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |
| Daewoong-Lilly Pharmaceutical Co. | |
Eli Lilly Australia Pty Ltd.
Eli Lilly Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Eli Lilly Australia Pty Ltd. manufactures and supplies pharmaceutical products. It develops medicines for diabetes, cancer, immunology, and pain. The company was founded in 1960 and is headquartered in West Ryde, Australia. | Health Technology |
- Stock Market
- Insiders
- Bryce D. Carmine
